Director Agriculture Jammu kick starts Kharif-2021 Campaign
Director Agriculture Jammu kick starts Kharif-2021 Campaign
New varieties of Basmati distributed among farmers
JAMMU, APRIL 17: Director Agriculture, Jammu, K. K. Sharma today kick started the Kharif 2021 campaign by conducting multiple interactions with the farmers in Sub-Division Marh and Sub Division Samba.
The visit was conducted to gear up the departmental activities at grassroots level in view of the upcoming Kharif season.
The team of officer including Joint Director Agriculture (Extension), Shahid Iqbal Sheikh, Chief Agriculture Officer Jammu, A.S. Reen, DAO (Extension), Vinod Sharma, Sub-Divisional Agriculture Officer Marh, Ashwani Kumar Jojra, AEO Pounichak, Tirth Singh and AEO Marh, Vikram Katayal accompanied the Director during the visit.
Global Contact Center Work Workforce Management Product and Market 2021-2022: New-Gen WFM - Uniquely Suited to Address Pandemic-Related Challenges and Beyond
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Das sind zentrale Bausteine des Prozessmanagements
computerwelt.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from computerwelt.at Daily Mail and Mail on Sunday newspapers.
10 Years Of Progress In 10 Months: 2020 Was A Reset Year For Pharma
By Ed Miseta, Chief Editor, Clinical Leader
Follow Me On Twitter @EdClinical
A new report from McKinsey & Company highlights why 2020, despite the COVID-19 pandemic, was a banner year for innovation in drug development, and why we should be optimistic for the future of the industry. The report, titled Biopharma 2020: A Landmark Year And A Reset For The Future, highlights 10 critical themes for pharma CEOs to consider as we move into 2021 and beyond.
There is no denying that 2020 was a watershed year for the industry. Despite the pandemic shutting down some trials and delaying others, much was accomplished. The report notes the industry progressed more in the last 10 months than it had in the prior 10 years. The biopharma industry has shown what it is capable of accomplishing when it works at its best. Companies that for years held back on implementing decentralized trials suddenly had them up and running in a mat